INVION LIMITED — AGM Information 2021

Nov 8, 2021

==> picture [1440 x 355] intentionally omitted <==

• ANNUAL GENERAL MEETING

9 NOVEMBER 2021

==> picture [171 x 58] intentionally omitted <==

©Copyright Invion Limited| A C N 094 730 417| A S X : I V X

==> picture [1440 x 141] intentionally omitted <==

CEO PRESENTATION

==> picture [171 x 58] intentionally omitted <==

2

KEY ACHIEVEMENTS HIGHLIGHTS OVER THE PAST YEAR

Progressing towards the commercialisation of the next-generation PDT treatment for major diseases

==> picture [91 x 88] intentionally omitted <==

==> picture [91 x 91] intentionally omitted <==

==> picture [91 x 91] intentionally omitted <==

==> picture [91 x 91] intentionally omitted <==

==> picture [91 x 91] intentionally omitted <==

Promising Results : Latest PoC studies showed evidence of complete regression of TNBC tumours and ongoing protective immunity

Improved API : Developed INV043 which is shown to have ~50 times greater phototoxicity than IVX-P03, better cancer targeting capabilities and strong therapeutic profile

• Expanded Markets : New agreement gives Invion exclusive rights to Asia Pacific (ex Greater China) for Atherosclerosis and Infections Diseases

World Leading Partnerships : Research collaboration with partner institutions, Hudson Institute of Medical Research and Peter MacCallum Cancer Centre

Cancer R&D Fully Funded : RMW Cho to pay all R&D cost for cancer-related development and part of the cost for Atherosclerosis and Infections Diseases

==> picture [171 x 58] intentionally omitted <==

IMPROVED API – INV043

KEY CHARACTERISTICS: INITIAL PROOF OF CONCEPT (PoC)

INV043 selected as lead Active Pharmaceutical Ingredient (API) for development of next-generation of PDT cancer treatments

• Promising preliminary results that may have application across a range of cancers

• INV043 has ~600 times greater than Talaporfin sodium (widely used photosensitiser) and ~50 times greater phototoxicity than Invion’s previous API (IVX-P03)

• Studies showed INV043 is selectively retained in malignant but not healthy tissues

• Significant regression was observed in vivo in T-cell lymphoma, triple negative breast and pancreatic cancer models (immune deficient in vivo models)

• INV043 also displayed fluorescence characteristics under blue light, which illuminated tumour growths

• No toxicity issues were identified up to 50x the therapeutic dose

==> picture [35 x 52] intentionally omitted <==

----- Start of picture text -----

C.
----- End of picture text -----

B. Phototo ~~xic~~ ity INV043 vs IVX-P03 vs Talaporfin Sodium

I ~~N~~ V ~~04~~ 3 ~~A~~ ctivity Against Multiple Cancer Cell Types

==> picture [375 x 197] intentionally omitted <==

----- Start of picture text -----

100
80 Ovarian (SKOV3)
Colorectal (DLD1)
60
Liver (HEK293)
40 T-cell Lymphoma (HH)
Lung (A549)
20
Triple Negative Breast
(MDA-MB-468)
0.001 0.01 0. 1 1
Photosensitizer ( µ M)
Viability (% of control)
----- End of picture text -----

==> picture [354 x 210] intentionally omitted <==

----- Start of picture text -----

100
80
INV043
Talaporfin Sodium
60
IVX-P03
40
20
0.01 0.1 1 10
Photosensitizer ( µ M)
Viability (% of control)
----- End of picture text -----

C. Theragnostic Potential

• A. INV043 is Active Against Multiple Cancer Types with IC90 (concentration required to kill 90% of cells) as low as 30nM against some cancer types

==> picture [209 x 207] intentionally omitted <==

• B. INV043 had ~600 and ~50- fold greater phototoxicity than Talaporfin sodium and IVX-P03, respectively

• C. INV043 rapidly localised to cancer deposits . Within 24 hours INV043 not detectible in healthy tissues but remained concentrated within tumour mass >3 days. Fluorescence highlighted small metastatic nodules not visible to the naked eye

==> picture [171 x 58] intentionally omitted <==

PILOT PROOF OF CONCEPT RESULTS

SECOND PoC STUDY ON IMMUNOCOMPETENT MICE

Early signs that INV043 can completely regress Triple Negative Breast Cancer (TNBC) tumours and trigger protective immunity

• PoC pilot studies show complete regression of TNBC in vivo following INV043 treatment

• TNBC is a hard-to-treat cancer that is resistant to most chemotherapies (one of many cancer types where a strong clinical need exists for alternatives to current standard of care)

• Tumour mass was undetectable two weeks after initial treatment and no scarring was evident

• No recurrence of disease and re-challenge with TNBC implant could not re-establish new tumours, suggesting the development of protective immunity

• Non-toxic up to 100x the therapeutic dose

• Formulated for oral, injectable and topical delivery with tumour localisation via these routes successfully demonstrated

• Additional PoC tests being carried out by Hudson Institute

==> picture [436 x 380] intentionally omitted <==

==> picture [362 x 245] intentionally omitted <==

----- Start of picture text -----

Tumour volume
----- End of picture text -----

==> picture [171 x 58] intentionally omitted <==

NEW MARKET OPPORTUNITIES

EXPANDED TERRITORIES AND NEW DISEASE AREAS

==> picture [415 x 670] intentionally omitted <==

Invion signed Co-Development and Exclusive Distribution & Licence Agreements with RMW Cho

Both will co-develop Photosoft™technology for the treatment of atherosclerosis and infectious diseases (including viral, bacterial, fungal and parasitic)

Invion has exclusive distribution rights to the Photosoft™technology in Asia Pacific[1] for these indications

Invion paid RMW $2.25M for the rights that was funded via a successful $4.5M share placement

RMW and affiliates will continue funding Invion’s R&D activities for cancers under the existing R&D services agreement

Cancer remains a primary focus for Invion

==> picture [171 x 58] intentionally omitted <==

1 Asia Pacific includes Asia and Oceania (other than Australia and New Zealand, which are the subject of an existing distribution and licence agreement with RMW), and excludes Middle East, Russia and the specified territories of China, Hong Kong, Macau and Taiwan.

NEW MARKET OPPORTUNITIES

EXPANDED TERRITORIES AND NEW DISEASE AREAS

Invion’s exclusive territories gives it access to markets with >2.8 billion people

==> picture [136 x 204] intentionally omitted <==

Atherosclerosis

Disease where plaque builds up inside arteries.

Global treatment market is forecast to hit US$56.6 billion by 2027[1] , and . Asia Pacific is the fastest growing region[2]

Atherosclerosis is a major contributor to cardiovascular diseases – the . largest cause of death worldwide[3]

==> picture [136 x 203] intentionally omitted <==

Infectious Diseases

. Global market worth US$166.5bn by 2026 and growing at ~8% CAGR[4]

Environmental and climate change make infectious diseases more . challenging to control[5]

Global pandemic has highlighted need for new treatments.

1 https://www.marketwatch.com/press-release/atherosclerosis-drugs-market-size-share-trends-analysis-and-forecast-2027-2021-09-30

2 https://www.mordorintelligence.com/industry-reports/atherosclerosis-drugs-market

3 https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1

4 https://www.medgadget.com/2021/10/global-infectious-disease-therapeutics-market-size-to-grow-usd-166-46-billion-by-2026.html 5 https://www.sciencedirect.com/science/article/pii/S0160412015300489

==> picture [171 x 58] intentionally omitted <==

THE WAY FORWARD

PATHWAY TO CLINICAL TRIALS

Invion is on building early successes by identifying target cancer indications with our partner institutions whilst making pre-clinical preparations with a view to initiating clinical trials in more than one indication in 2022.

==> picture [829 x 317] intentionally omitted <==

----- Start of picture text -----

1H 2022 2H 2022
Clinical trial
indication targets
Conduct initial
Cancer Additional PoC
clinical trials
Pre-Clinical
Preparations
Early stage broad
Atherosclerosis and based discovery Continued discovery
Infectious Diseases
Identification of PoC on initial
(AID)
initial potential targeted indications
targets
----- End of picture text -----

• RMW Cho Group (“RMW”) is the inventor and licensor of Photosoft[TM] technology

• Invion’s cancer program is funded by RMW

• RMW is pursuing independent research in parallel with Invion’s R&D efforts including a prostate cancer trial

• The research is complementary/supplemental to Invion’s development program

• To the extent that Invion becomes aware of material information relating to RMW’s studies, Invion will release the information to the ASX in compliance with its disclosure obligations (noting however that Invion is not involved in RMW’s studies and does not have direct access to information).

==> picture [171 x 58] intentionally omitted <==